噻托溴铵联合沙美特罗替卡松粉吸入剂吸入治疗中重度稳定期COPD的临床研究

目的探讨噻托溴铵联合沙美特罗替卡松粉吸人剂吸人治疗中重度稳定期慢性阻塞性肺疾病（COPD）的临床效果。方法回顾性分析57例中重度稳定期COPD患者的临床资料，将患者随机分为对照组（n=28，单用沙美特罗替卡松粉吸入剂治疗）和实验组（n=29，在对照组基础上加用噻托溴铵治疗）。治疗3个月后，比较两组的临床症状评分、肺功能指标的变化及不良反应发生率。结果治疗前，两组的临床症状评分、肺功能指标比较，差异无统计学意义（P〉0．05）；治疗3个月后，实验组的临床症状评分明显低于对照组，肺功能指标高于对照组，不良反应发生率显著低于对照组（P〈0．05）。结论中重度稳定期COPD应用噻托溴铵联合沙美特罗替卡松粉吸入剂吸入治疗可显著改善患者的临床症状和肺功能，不良反应少，值得临床推广。

The clinical study of inhalation therapy of tiotropium combined with salmeterol xinafoate and fluticasone propionate powder inhalation treating moderate-severe COPD in stable period

Objective To Investigate the clinical effect of tiotropium combined with salmeterol xinafoate and fluticasone propionate powder inhalation treating moderate-moderate-severemoderate-severesevere chronic obstructive pulmonary disease （COPD）. in stable period. Methods The clinical data of 57 patients with moderate-severe COPD in stable period were retrospectively analyzed and patients were randomly divided into the control group （n=28,they were treat- ed by salmeterol xinafoate and fluticasone propionate powder inhalation） and the experimental group （n=29,they were treated by tiotropium based on the treatment of the control group.After 3 months treatment,clinical symptom score,1 changes of lung function indicators and incidence rate of adverse reactions in the two groups were compared. Results There was no statistical difference of the clinical symptom score,lung function and other indicators in the two groups （P〉0.05） before treatment;after 3 months treatment,clinical symptom score in the experimental group was obviously lower than that in the control group,lung function indicators in the experimental group were higher than that in the control group, the incidence rate in the experimental group as obviously than that in the control group （P〈0.05）. Conclusion Treating moderate-severe COPD in stable period with tiotropium inhalation combined with salmeterol xinafoate and fluticasone propionate powder inhalation can significantly improve the clinical symptoms and lung function of patients,it has less adverse reactions.It is worthy of clinical promotion.